Manufacturer's investigation conclusion: a direct correlation between heartmate (hm) 3 left ventricular assist system (lvas) and the report of deep vein thrombosis (dvt)/ pericatheter thrombus could not be conclusively determined through this evaluation.The patient remains ongoing on hm3 lvas.No further related events have been reported at this time.The relevant sections of the device history records were reviewed and showed no deviations from manufacturing or quality assurance specifications.The implant kit was shipped on 24may2022 the heartmate 3 lvas ifu is currently available.Section 1 of the ifu, ¿introduction¿, lists peripheral thromboembolic event as a potential adverse event that may be associated with the use of the heartmate 3 left ventricular assist system.Section 6 of the ifu, ¿patient care and management¿, lists thromboembolism as a potential late postimplant complication.Section 6 of the ifu, under ¿anticoagulation¿, provides information regarding the recommended anticoagulation regimen, including inr values, as well as suggested anticoagulation modifications.No further information was provided.The manufacturer is closing the file on this event.
|